Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-12-06
1998-08-18
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3141
Patent
active
057959048
ABSTRACT:
Losartan, its active metabolite, EXP3174, or the pharmaceutically acceptable salts of these compounds for use in enhancing the functional recovery of the heart after an ischemic attack.
REFERENCES:
patent: 5538991 (1996-07-01), Ashton et al.
patent: 5565485 (1996-10-01), Bagley et al.
Thomas et al, CA 125: 238142, 1996.
Fleetwood, G., eta l., "Involvement of the Renin-Angiotension System in Ischemic Damage and Reperfusion Arrhythmias in the Isolated Perfused Rat Heart", J. of Cardio. Pharm., vol. 17, pp. 351-356, 1991.
Yoshiyama, M., et al., "Cardioprotective Effect of the Angiotension II Type 1 Receptor Antagonist TCV-116 on Ischemia-Reperfusion Injury", Clinical Investigations, vol. 128(1), pp. 1-6, 1994.
Werrmann, J.G. et al, "Comparison of Effects of Angiotensin-Converting Enzyme Inhibition with those of Angiotensin II Receptor Antagonism on Functional and Metabolic Recovery in Postischemic Working Rat Heart as 24, pp. 573-586, 1994.
Cohen Sheila M.
Werrmann Jeffrey G.
Camara Valerie J.
Cook Rebecca
Daniel Mark R.
Merck & Co. , Inc.
LandOfFree
Enhanced functional recovery of the heart by losartan treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced functional recovery of the heart by losartan treatment , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced functional recovery of the heart by losartan treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1115070